# Enkang

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/enkang

- Industry: Pharmaceuticals
- Headquarters: Guangzhou, China
- Website: www.ek-pharma.com
- Latest round: Series B (Jan 30, 2023)
- Investors on record: 1

## About

Founded in 2017 and based in Guangzhou, China, Enkang is a pharmaceutical technology company that focuses on the development of anti-cancer drugs. The company has R&D laboratories and product pilot workshops in Hong Kong, Macao, Guangzhou and Foshan. By 2023, it has applied for 15 invention patents at home and abroad, including 7 patents. Chun Liang, the founder, chairman and chief scientist of the company, is now a tenured professor of the life sciences department of the Hong Kong University of Science and Technology and the director of the Cancer Research Center of the Hong Kong University of Science and Technology. In May 2025, it closed a venture funding.

The company's main business is the R & D of innovative anti-cancer drugs and pharmaceutical formulations. The company's self-developed products include the inhaled liposome drug ILC (Inhaled Lipid Cisplatin) for small cell lung cancer and the DRIPs inhibitor EN002 gel for non-melanoma skin cancer and pre-cancer lesions. It also has two R & D platforms: the inhaled liposome formulation platform and the DRIP (DNA replication initiation protein) inhibitor-targeted tumor drug screening platform. Its products are used in the field of oncology for cancer treatment.

## Funding rounds

- Series B, Jan 30, 2023 — Cherami Investment Group

## Investors

- Cherami Investment Group (https://capitalatlas.ai/funds/cherami-investment-group) — Series B